{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:43Z","timestamp":1793766463852,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102611","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:38:51Z","timestamp":1782862731000},"page":"102611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex-Specific Differences in Disease-Free, Progression-Free and Overall Survival Following Enfortumab Vedotin Therapy for Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-8654","authenticated-orcid":false,"given":"Laila","family":"Schneidewind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Zengerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujza","family":"Brunaiova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"R\u00f6thlisberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Graser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102611_bib0001","unstructured":"International Agency for Research on Cancer. Estimated number of new cases in 2020, worldwide, both sexes, all ages. Available at: https:\/\/shorturl.at\/EcVkm [Access: March, 18 2026]"},{"key":"10.1016\/j.clgc.2026.102611_bib0002","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00120-025-02665-8","article-title":"Gender-specific differences in outcome and survival in early cystectomy: systematic review","volume":"65","author":"Schneidewind","year":"2026","journal-title":"Urologie"},{"key":"10.1016\/j.clgc.2026.102611_bib0003","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102611_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2011.03.047","article-title":"Trends in mortality from urologic cancers in Europe, 1970-2008","volume":"60","author":"Bosetti","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102611_bib0005","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s11255-015-0980-6","article-title":"The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients","volume":"47","author":"Liu","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.clgc.2026.102611_bib0006","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.euf.2019.06.001","article-title":"Sex-specific differences in the quality of treatment of muscle-invasive bladder cancer do not explain the overall survival discrepancy","volume":"7","author":"Krimphove","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2026.102611_bib0007","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cncr.28416","article-title":"Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation","volume":"120","author":"Cohn","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2026.102611_bib0008","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ejca.2010.10.007","article-title":"Parity, early menopause and the incidence of bladder cancer in women: a case- control study and meta-analysis","volume":"47","author":"Dietrich","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2026.102611_bib0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.23986","article-title":"Sex and racial differences in bladder cancer presentation and mortality in the US","volume":"115","author":"Scosyrev","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2026.102611_bib0010","article-title":"Re: sex and racial differences in bladder cancer presentation and mortality in the US","volume":"57","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102611_bib0011","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ije\/dyz264","article-title":"The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nurses\u2019 Health Study and Nurses\u2019 Health Study II","volume":"49","author":"Abufaraj","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.clgc.2026.102611_bib0012","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102611_bib0013","unstructured":"Cochrane Germany, Institut f\u00fcr Medizinische Biometrie und Statistik, Freiburg, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften- Institut f\u00fcr Medizinisches Wissensmanagement, \u00e4rztliches Zentrum f\u00fcr Qualit\u00e4t in der Medizin. Manual zur Bewertung des Biasrisikos in Interventionsstudien. 2nd Edition 2021. Cochrane Germany: https:\/\/www.cochrane.de\/de\/literaturbewertung: doi: 10.6094\/UNIFR\/194900"},{"key":"10.1016\/j.clgc.2026.102611_bib0014","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/biom.13332","article-title":"Variance estimation in inverse probability weighted Cox models","volume":"77","author":"Shu","year":"2021","journal-title":"Biometrics"},{"key":"10.1016\/j.clgc.2026.102611_bib0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clgc.2026.102611_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clgc.2026.102611_bib0017","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1017\/rsm.2024.5","article-title":"Reducing the biases of the conventional meta-analysis of correlations","volume":"16","author":"Stanley","year":"2025","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.clgc.2026.102611_bib0018","first-page":"4","article-title":"Meta: an R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"key":"10.1016\/j.clgc.2026.102611_bib0019","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s11523-024-01099-0","article-title":"Enfortumab vedotin following platinum chemotherapy and avelumab maintenance in patients with metastatic urothelial carcinoma: a retrospective data from the ARON-2(EV) study","volume":"19","author":"Fiala","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.clgc.2026.102611_bib0020","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.21873\/invivo.13961","article-title":"Steroid premedication impact on efficacy and cutaneous toxicity of enfortumab vedotin for advanced urothelial carcinoma","volume":"39","author":"Furubayashi","year":"2025","journal-title":"In Vivo"},{"key":"10.1016\/j.clgc.2026.102611_bib0021","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/jjco\/hyae082","article-title":"Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study","volume":"54","author":"Hayakawa","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102611_bib0022","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 Amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102611_bib0023","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/iju.15686","article-title":"Influence of best objective response to first-line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin","volume":"32","author":"Kobatake","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2026.102611_bib0024","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.21873\/anticanres.17162","article-title":"Clinical outcomes of enfortumab vedotin in advanced urothelial carcinoma with prior avelumab versus pembrolizumab therapy","volume":"44","author":"Minato","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2026.102611_bib0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10147-024-02672-3","article-title":"Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response","volume":"30","author":"Nagayama","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102611_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102301","article-title":"Enfortumab Vedotin for metastatic urothelial carcinoma: comprehensive treatment outcomes and prognostic insights from a multicenter real-world study (YUSHIMA Study)","volume":"23","author":"Nakamura","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102611_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102278","article-title":"Real-world evidence for enfortumab vedotin in patients with metastatic urothelial cancer: an Austrian multicentre study","volume":"23","author":"Niedersuess-Beke","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102611_bib0028","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/iju.70030","article-title":"Impact of skin adverse events on prognosis in patients with locally advanced or metastatic urothelial carcinoma treated with Enfortumab Vedotin: a real-world multicenter study","volume":"32","author":"Ozaki","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2026.102611_bib0029","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102611_bib0030","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102611_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.102183","article-title":"Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: a multicenter retrospective study","volume":"16","author":"Shindo","year":"2025","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clgc.2026.102611_bib0032","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10147-025-02709-1","article-title":"Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium","volume":"30","author":"Uchimoto","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102611_bib0033","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/jjco\/hyaf060","article-title":"Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study","volume":"55","author":"Urabe","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102611_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1377842","article-title":"Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience","volume":"14","author":"Vlachou","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102611_bib0035","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2011201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102611_bib0036","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.1007\/s00432-023-04640-2","article-title":"GNRH family genes contributed to gender-specific disparity of bladder cancer prognosis through exerting opposite regulatory roles between males and females","volume":"149","author":"Song","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102611_bib0037","first-page":"34","article-title":"The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy","volume":"8","author":"Zhou","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.clgc.2026.102611_bib0038","first-page":"21","article-title":"A systematic review and network meta-analysis of first-line immunotherapy for advanced urothelial carcinoma","volume":"9","author":"Liu","year":"2026","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.clgc.2026.102611_bib0039","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s10020-025-01199-1","article-title":"Genomic subtypes of non-muscle-invasive bladder cancer: guiding immunotherapy decision-making for patients exposed to aristolochic acid","volume":"31","author":"Peng","year":"2025","journal-title":"Mol Med"},{"key":"10.1016\/j.clgc.2026.102611_bib0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13293-025-00715-6","article-title":"Sex differences in bladder cancer: understanding biological and clinical implications","volume":"16","author":"Chaudhary","year":"2025","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.clgc.2026.102611_bib0041","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00120-025-02557-x","article-title":"Association of glitazones and bladder cancer: a rapid review","volume":"64","author":"Schneidewind","year":"2025","journal-title":"Urologie"},{"key":"10.1016\/j.clgc.2026.102611_bib0042","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.euo.2024.03.014","article-title":"Effect of sex on the oncological outcomes in response to immunotherapy and antibody-drug conjugates in patients with urothelial and kidney cancer: a systematic review and a network meta-analysis","volume":"7","author":"Cerrato","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:17:07Z","timestamp":1793765827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1558767326001114"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102611","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex-Specific Differences in Disease-Free, Progression-Free and Overall Survival Following Enfortumab Vedotin Therapy for Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102611"}}